EUVIMEDEUVIMED entdecken
Crossref

Cardiovascular safety of romosozumab versus alendronate in postmenopausal women with severe osteoporosis: a propensity-matched real-world study

Gizem Teker, Sara Ramadan, Ali Emre Bardak, Sezan Vehbi, Smuch Siramongkholkarn, Zhiheng He

Journal of Bone and Mineral Metabolism · 30.10.2026

DOI: 10.1007/s00774-026-01775-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Bone and Mineral Metabolism, online erschienen am 30.10.2026. Verfasst von Gizem Teker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Boston, MA, USA. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

AlendronateCardiovascular SafetyMajor Adverse Cardiovascular EventsPostmenopausal OsteoporosisRomosozumab

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Department of Medicine, Boston Medical Center - Brighton, 736 Cambridge St, Boston, MA, 02135, USA. sramadan@bu.edu.
  • Department of Medicine, Boston Medical Center - Brighton, 736 Cambridge St, Boston, MA, 02135, USA.
  • Division of Endocrinology, Boston Medical Center - Brighton, Boston, MA, USA.

Zitieren

APA

Teker, G., Ramadan, S., Bardak, A. E., Vehbi, S., Siramongkholkarn, S., & He, Z. (2026). Cardiovascular safety of romosozumab versus alendronate in postmenopausal women with severe osteoporosis: a propensity-matched real-world study. Journal of Bone and Mineral Metabolism. https://doi.org/10.1007/s00774-026-01775-3

Vancouver

Teker G, Ramadan S, Bardak AE, Vehbi S, Siramongkholkarn S, He Z. Cardiovascular safety of romosozumab versus alendronate in postmenopausal women with severe osteoporosis: a propensity-matched real-world study. Journal of Bone and Mineral Metabolism. 2026. doi:10.1007/s00774-026-01775-3

BibTeX
@article{Teker2026,
  author = {Teker, Gizem and Ramadan, Sara and Bardak, Ali Emre and Vehbi, Sezan and Siramongkholkarn, Smuch and He, Zhiheng},
  title = {Cardiovascular safety of romosozumab versus alendronate in postmenopausal women with severe osteoporosis: a propensity-matched real-world study},
  journal = {Journal of Bone and Mineral Metabolism},
  year = {2026},
  doi = {10.1007/s00774-026-01775-3}
}
Kostenlos starten →